-0.00071088065568293 -0.00160993560257598 0.000250899054946903 -0.0010245044743665 -0.00564522873630519 -0.00140085305678685 -0.00200719243957522 -0.00200719243957522
Sign Up Today X
Thanks for submitting the form.
Stockreport

Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch [Seeking Alpha]

Vertex Pharmaceuticals Incorporated (VRTX)  More Company Research Source: Seeking Alpha
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
CASGEVY revenue recognition is delayed due to Vertex's cost recoupment, but patient infusions are accelerating and geographic expansion continues. CRSP's pipeline focus shifts to CTX310 for dyslipidemia and CTX611 siRNA for VTE prophylaxis, with Phase 2 TKA data for 611 as a major 2026 catalyst. Despite $1.98B in cash affording 3-4 years of runway, CRSP must deliver breakthrough results in crowded markets to justify R&D intensity and achieve breakeven. J Studios/DigitalVision via Getty Images Overview I've covered CRISPR Therapeutics ( CRSP ) for quite a while now. Until just recently, my focus has predominantly been on its ex vivo sickle cell disease gene therapy product, CASGEVY, which it co-markets with Vertex Pharmaceuticals ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, a [Read more]
IMPACT SNAPSHOT EVENT TIME: VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VRTX alerts
from News Quantified
VRTX
NEWS
VRTX
Earnings
VRTX
Analyst Actions
VRTX
SEC Filings
Stockreport

Crispr: Emphasis Shifts To Cardiovascular Pipeline Amid Slow Casgevy Launch [Seeking Alpha]

Vertex Pharmaceuticals Incorporated  (VRTX) 
More Company Research Source: Seeking Alpha
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.vrtx.com
CASGEVY revenue recognition is delayed due to Vertex's cost recoupment, but patient infusions are accelerating and geographic expansion continues. CRSP's pipeline focus shifts to CTX310 for dyslipidemia and CTX611 siRNA for VTE prophylaxis, with Phase 2 TKA data for 611 as a major 2026 catalyst. Despite $1.98B in cash affording 3-4 years of runway, CRSP must deliver breakthrough results in crowded markets to justify R&D intensity and achieve breakeven. J Studios/DigitalVision via Getty Images Overview I've covered CRISPR Therapeutics ( CRSP ) for quite a while now. Until just recently, my focus has predominantly been on its ex vivo sickle cell disease gene therapy product, CASGEVY, which it co-markets with Vertex Pharmaceuticals ( This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, a [Read more]
IMPACT SNAPSHOT
EVENT TIME:
VRTX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS